Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy [Yahoo! F...
ONO PHARM CO UNSP/ADR (OPHLY)
NASDAQ:AMEX Investor Relations:
ono.co.jp/eng/investor/index.html
Company Research
Source: Yahoo! Finance
Phase 2 clinical trial was conducted in early multiple system atrophy patients within 5 years of symptom onset in Japan and the US Multiple system atrophy is a neurodegenerative disease with poor prognosis and no approved disease-modifying treatments ONO-2808, a selective S1P5 receptor agonist, could be a first-in-class treatment for patients with multiple system atrophy OSAKA, Japan, October 09, 2025 BUSINESS WIRE )--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") announced that efficacy signals for ONO-2808, a S1P5 receptor agonist, were observed in the interim analysis of the Phase 2 clinical trial ( ONO-2808-03 study ) which assessed the safety and efficacy of ONO-2808 compared to placebo in patients with multiple system atrophy (MSA). In the exploratory interim analysis of this study, it was observed that the progression of MSA tended to be slower in the ONO-2808 group in terms of the clinical outcome endpoint, Unified Mul
Show less
Read more
Impact Snapshot
Event Time:
OPHLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPHLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPHLY alerts
High impacting ONO PHARM CO UNSP/ADR news events
Weekly update
A roundup of the hottest topics
OPHLY
News
- Deciphera Announces the Opening of a New Office in Zug, Switzerland [Yahoo! Finance]Yahoo! Finance
- Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025 [Yahoo! Finance]Yahoo! Finance
- Ono Announces ONO-4578 (EP4 antagonist) in Combination with Opdivo and Chemotherapy Met the Primary Endpoint in a Phase 2 Clinical Trial in Patients with Certain Gastric Cancer [Yahoo! Finance]Yahoo! Finance
- Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment [Yahoo! Finance]Yahoo! Finance
- Is Now the Right Moment for Ono Pharmaceutical Shares Amid Sector Recovery in 2025? [Yahoo! Finance]Yahoo! Finance